Article
Selective LXR agonist, DMHCA, corrects the retina-bone marrow axis in type 2 diabetes
medRxiv · 2020 · Cristiano P. Vieira
Key facts
| Title | Selective LXR agonist, DMHCA, corrects the retina-bone marrow axis in type 2 diabetes |
|---|---|
| First author | Cristiano P. Vieira |
| Journal | medRxiv |
| Published | Feb 12, 2020 |
| DOI | 10.1101/2020.02.11.942292 |
| Devices mentioned | K090413, K152294, K233719, K800552, K853723, K860811, K862004, K874160, K874609, K912581, K915561, K915840 and 13 more |
| Product codes mentioned | EPT, GCJ, GCT, GEX, HET, HJO, HLI, HLQ, HQF, KKX, KPR, LCP and 4 more |
At a glance
- 10–99 FDA submissions mentioned
- 10–99 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1